An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery.

Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. · 2017

Read An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery. by Mohammed MA, Syeda JTM, Wasan KM, Wasan EK. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5750659.txt.

Introduction

Mohammed and co-authors review chitosan nanoparticles for drug delivery without needles. Chitosan is a safe, degradable polymer that breaks down in the body. Its particles carry a positive charge and stick to mucus. That makes them fit for mouth, nose, lung, and eye routes.

The review covers chitosan traits, chemical changes, and safety data. It also covers how the body handles these particles. Uses include cancer, gut and lung disease, brain delivery, and eye infection. Slow, sustained release is a key strength of the forms. Recent studies and early test work are summed up.

Catalog record

CREATORMohammed MA, Syeda JTM, Wasan KM, Wasan EK.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE77 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5750659

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery By Munawar A. Mohammed, Jaweria T. M. Syeda, Kishor M. Wasan, Ellen K. Wasan Published in: Pharmaceutics DOI: 10.3390/pharmaceutics9040053 ABSTRACT The focus of this review is to provide an overview of the chitosan based nanoparticles for various non-parenteral applications and also to put a spotlight on current research including sustained release and mucoadhesive chitosan dosage forms. Chitosan is a biodegradable, biocompatible polymer regarded as safe for human dietary use and approved for wound dressing applications. Chitosan has been used as a carrier in polymeric nanoparticles for drug delivery through various routes of administration. Chitosan has chemical functional groups that can be modified to achieve specific goals, making it a polymer with a tremendous range of potential applications. Nanoparticles (NP) prepared with chitosan and chitosan derivatives typically possess a positive surface charge and mucoadhesive properties such that can adhere to mucus membranes and release the drug payload in a sustained release manner. Chitosan-based NP have various applications in non-parenteral drug delivery for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections which will be exemplified in this review. Chitosan shows low toxicity both in vitro and some in vivo models. This review explores recent research on chitosan based NP for non-parenteral drug delivery, chitosan properties, modification, toxicity, pharmacokinetics and preclinical studies. 1. INTRODUCTION The mucosal route is gaining attention for noninvasive drug delivery via the oral, nasal, pulmonary or vaginal routes [1]. At the same time, nanoparticle technology has also come to the forefront as a viable drug delivery strategy, presenting opportunities for controlled release, protection of active components from enzymatic or environmental degradation and localized retention. Nanoparticle fabrication methods are readily scalable and applicable to a broad range of drugs. Of all the nanoparticle drug delivery approaches, polymeric nanoparticles have gained significant importance as they are biodegradable, biocompatible and because formulation methods are more widely available; the range of applications has been expanding to include a variety of chemical drug classes and dosage forms [2]. Chitosan-based NP are particularly appropriate for the mucosal route, with their low toxicity, mucoadhesion and tunable physical properties. Examples will be given of chitosan-based nanoparticles used for the treatment of cancer, gastrointestinal diseases, pulmonary diseases, drug delivery to the brain and ocular infections. Recent research on chitosan-based NP for nonparenteral drug delivery is based on the field’s expanding understanding of chitosan properties and methods of chemical or physical modification, which are applied to the optimization of nanoparticle drug loading and release features. We will also discuss the current understanding of in vitro and in vivo toxicity and the effect of chitosan nanoparticle formulation on drug pharmacokinetics in preclinical studies. Chitosan Chitosan is the most important derivative of chitin, produced by removing the acetate moiety from chitin as shown in Figure 1. It is derived from crustacean shells such as those from prawns or crabs, as well as from the cell walls of fungi. It is a naturally occurring polysaccharide, cationic, highly basic, mucoadhesive biocompatible polymer and approved by the U.S. FDA for tissue engineering and drug delivery. Chitin from natural sources is found bound to proteins and minerals, which must be removed prior to preparation of chitosan, though processes of acidification and alkalization. Purified chitin is then N-deacetylated to chitosan. This process can be modified to control the end product properties [including molecular weight and pKa (6–7.5)] [3,4] by controlling the degree of deacetylation with factors such as reaction conditions (concentration, ratios of chitin to alkali, temperature), chitin source and extent of the reaction, for example. While these chemical processes are well in hand for industrial processors, research is ongoing to more fully develop scalable biological, enzymatic or hybrid methods such as those using microorganisms [5]. It will be interesting to see how these approaches will be used to manufacture specific types of deacetylated chitosan and whether these bioprocesses will have any environmental advantage in the future. Chitosan acts a penetration enhancer by opening the tight junctions of the epithelium. Chitosan facilitates both paracellular and transcellular transport of drugs as indicated in Figure 2. Chitosan interacts with mucus (negatively charged) to form a complex by ionic or hydrogen bonding as well as though hydrophobic interactions. The pKa of the primary amine of chitosan is ~6.5, depending on the degree of N-deacetylation. This group also contributes to the solubility of chitosan in acidic pH environments and the partial neutralization of this primary amine may also explain why chitosan has been reported to aggregate at neutral to high pH [6]. However, it should be noted that while this may be the tendency for chitosan with fraction of acetylated units <0.4 and medium/high molecular weight, chitosan with acetylation degrees in the range 40–60% are well known as being soluble even at physiological pH [4]. Thus, the nanoparticle formulator must carefully match the desired chemical and physical properties of the chitosan, as well as the anticipated biological environment, with the chitosan processing method. 2. MODIFICATION OF CHITOSAN The chitosan backbone can be modified to alter properties such as solubility, mucoadhesion and stability as discussed throughout this paper for specific applications. Both the -NH2 and -OH groups of chitosan are the active sites for modification. Some of the commonly used techniques described below for preparing chitosan polymers are: blending, graft co-polymerization and curing [7]. Blending involves the simple mixing of two or more polymers. Graft co-polymerization involves the covalent bonding of polymers, while curing converts the polymers into a solidified mass by formation of three-dimensional bonds within the polymer mass by means of thermal, electrochemical or ultraviolet radiation processing methods. 2.1. Physical Modification Physical modification is achieved by blending, which involves the physical mixing of two or more polymers. It is one of the oldest and easiest ways of modifying polymers. The quality and performance of the blend can be modified depending on the ratios of the polymers which are being mixed. Blending is the most economical technique by which the polymer properties can be tailored for specific applications [8]. Some of the common hydrophilic polymers that can be blended with chitosan to achieve oral drug delivery are poly (vinyl alcohol) (PVA), poly (vinyl pyrrolidone) (PVP) and poly (ethyl oxide) (PEO). Blending of chitosan and PVA improves the mechanical (tensile strength) and barrier properties (water vapor permeability) of chitosan films [9]. The intermolecular interactions between chitosan and PVA result in blends of PVA-chitosan that show improved mechanical properties (tensile strength) of chitosan films for controlled drug delivery [10]. An example of physical modification in controlled drug delivery is represented by amoxicillin formulated with a crosslinked chitosan/PVP blend with glutaraldehyde to form a semi-interpenetrating polymer (semi-IPN) [11]. The semi-IPN is formed because of the protonation of the amino group of chitosan, as confirmed by Fourier transform infrared spectroscopy (FTIR). Additional methods used for characterization of chitosan blends other than FTIR are: differential scanning calorimetry (DSC) [12], X-ray diffraction (XRD) [13], FTIR spectroscopy and rheology [14], enabling an understanding of the effects of processing on bonding and flow properties. 2.2. Chemical Modification Chemical modification is achieved by altering the functional groups in a compound. Chemical modification can be done by several ways which

Read the complete text